Vir Biotechnology News

Vir Biotechnology Analyst Ratings

BenzingaMar 15 09:25 ET

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and IN8bio (INAB)

TipRanksMar 15 06:20 ET

Buy Rating Affirmed for Vir Biotechnology on Promising HDV and HBV Programs and Strategic Market Positioning

TipRanksMar 11 00:46 ET

Optimistic Outlook for Vir Biotechnology's Clinical Programs and Financial Position Reinforces Buy Rating

TipRanksFeb 25 23:29 ET

Vir Biotechnology Analyst Ratings

BenzingaFeb 23 12:32 ET

Maintaining Hold on Vir Biotechnology Amid Revenue Decline and Strategic Pivot

TipRanksFeb 23 07:16 ET

Barclays Issues a Buy Rating on Vir Biotechnology (VIR)

TipRanksFeb 23 03:05 ET

Vir Biotechnology Analyst Ratings

BenzingaFeb 14 06:39 ET

JP Morgan Cuts Vir to Neutral, Cites Hepatitis Drug Franchise Concerns

Seeking AlphaJan 29 14:19 ET

JP Morgan Downgrades Vir Biotechnology to Neutral, Lowers Price Target to $9

BenzingaJan 29 06:06 ET

Vir Biotechnology Analyst Ratings

BenzingaJan 29 06:04 ET

Vir Biotechnology Analyst Ratings

BenzingaJan 23 06:40 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Airsculpt Technologies, Inc. (AIRS), Vir Biotechnology (VIR) and Gilead Sciences (GILD)

TipRanksNov 20, 2023 01:40 ET

Analysts' Top Healthcare Picks: Moleculin Biotech (MBRX), Vir Biotechnology (VIR)

TipRanksNov 14, 2023 12:20 ET

Vir Biotechnology's Promising Phase 2 Trials Propel Buy Rating: A Focus on HDV and HBV Treatment Advancements

TipRanksNov 14, 2023 01:58 ET

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MacroGenics (MGNX) and Outlook Therapeutics (OTLK)

TipRanksNov 7, 2023 06:20 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vir Biotechnology (VIR) and Atara Biotherapeutics (ATRA)

TipRanksNov 6, 2023 05:11 ET

Buy Rating for Vir Biotechnology: Expanding Initiatives and Promising Pipeline Amidst Financial Stability

TipRanksNov 6, 2023 01:10 ET

Needham Maintains Buy on Vir Biotechnology, Lowers Price Target to $15

BenzingaNov 3, 2023 07:22 ET

Vir Biotechnology Analyst Ratings

BenzingaNov 3, 2023 07:21 ET